Toward the identification of selective modulators of protein kinase C (PKC) isozymes: establishment of a binding assay for PKC isozymes using synthetic C1 peptide receptors and identification of the critical residues involved in the phorbol ester binding - PubMed (original) (raw)
Toward the identification of selective modulators of protein kinase C (PKC) isozymes: establishment of a binding assay for PKC isozymes using synthetic C1 peptide receptors and identification of the critical residues involved in the phorbol ester binding
M Shindo et al. Bioorg Med Chem. 2001 Aug.
Abstract
Conventional and novel protein kinase C (PKC) isozymes contain two cysteine-rich C1 domains (C1A and C1B), both of which are candidate phorbol-12,13-dibutyrate (PDBu) binding sites. We previously synthesized C1 peptides (of approximately 50 residues) corresponding to all PKC isozymes and measured their PDBu binding affinity. While many of these peptide receptors exhibited PDBu affinities comparable to the respective complete isozyme, some of the C1A peptides could not be used because they undergo temperature dependent inactivation. This problem was however eliminated by 4 degrees C incubation or elongation of the 50-mer C1 peptides at both N- and C-termini to increase their folding efficiency and stability. These findings enabled us to determine the K(d)'s of PDBu for all PKC C1 peptides (except for theta-C1A) and establish the value of these peptides as readily available, stable, and easily handled surrogates of the individual isozymes. The resultant C1 peptide receptor library can be used to screen for new ligands with PKC isozyme and importantly C1 domain selectivity. Most of the C1 peptide receptors showed strong PDBu binding affinities with K(d)'s in the nanomolar range (0.45-7.4 nM). Two peptides (delta-C1A and theta-C1A) bound PDBu over 100-fold less tightly. To identify the residues that contribute to this affinity difference, several mutants of delta-C1A and theta-C1A were synthesized. Both the G9K mutant of delta-C1A and the P9K mutant of theta-C1A showed K(d)'s of 2-3 nM. This approach provides a useful procedure to determine the role of each C1 domain of the PKC isozymes by point mutation.
Similar articles
- Establishment of a binding assay for protein kinase C isozymes using synthetic C1 peptides and development of new medicinal leads with protein kinase C isozyme and C1 domain selectivity.
Irie K, Nakahara A, Nakagawa Y, Ohigashi H, Shindo M, Fukuda H, Konishi H, Kikkawa U, Kashiwagi K, Saito N. Irie K, et al. Pharmacol Ther. 2002 Feb-Mar;93(2-3):271-81. doi: 10.1016/s0163-7258(02)00196-1. Pharmacol Ther. 2002. PMID: 12191619 Review. - Tumor promoter binding of the protein kinase C C1 homology domain peptides of RasGRPs, chimaerins, and Unc13s.
Irie K, Masuda A, Shindo M, Nakagawa Y, Ohigashi H. Irie K, et al. Bioorg Med Chem. 2004 Sep 1;12(17):4575-83. doi: 10.1016/j.bmc.2004.07.008. Bioorg Med Chem. 2004. PMID: 15358285 - Synthesis and phorbol ester binding of the cysteine-rich domains of diacylglycerol kinase (DGK) isozymes. DGKgamma and DGKbeta are new targets of tumor-promoting phorbol esters.
Shindo M, Irie K, Masuda A, Ohigashi H, Shirai Y, Miyasaka K, Saito N. Shindo M, et al. J Biol Chem. 2003 May 16;278(20):18448-54. doi: 10.1074/jbc.M300400200. Epub 2003 Mar 5. J Biol Chem. 2003. PMID: 12621060 - Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes.
Irie K, Nakagawa Y, Ohigashi H. Irie K, et al. Curr Pharm Des. 2004;10(12):1371-85. doi: 10.2174/1381612043384907. Curr Pharm Des. 2004. PMID: 15134488 Review.
Cited by
- Topological Heterogeneity of Protein Kinase C Modulators in Human T-Cells Resolved with In-Cell Dynamic Nuclear Polarization NMR Spectroscopy.
Overall SA, Hartmann SJ, Luu-Nguyen QH, Judge P, Pinotsi D, Marti L, Sigurdsson ST, Wender PA, Barnes AB. Overall SA, et al. J Am Chem Soc. 2024 Oct 9;146(40):27362-27372. doi: 10.1021/jacs.4c05704. Epub 2024 Sep 25. J Am Chem Soc. 2024. PMID: 39322225 Free PMC article. - Insertion Depth Modulates Protein Kinase C-δ-C1b Domain Interactions with Membrane Cholesterol as Revealed by MD Simulations.
Judge PT, Overall SA, Barnes AB. Judge PT, et al. Int J Mol Sci. 2023 Feb 27;24(5):4598. doi: 10.3390/ijms24054598. Int J Mol Sci. 2023. PMID: 36902029 Free PMC article. - Role and Mechanism of PKC-δ for Cardiovascular Disease: Current Status and Perspective.
Miao LN, Pan D, Shi J, Du JP, Chen PF, Gao J, Yu Y, Shi DZ, Guo M. Miao LN, et al. Front Cardiovasc Med. 2022 Feb 15;9:816369. doi: 10.3389/fcvm.2022.816369. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35242825 Free PMC article. Review. - Structural determinants of phorbol ester binding activity of the C1a and C1b domains of protein kinase C theta.
Czikora A, Pany S, You Y, Saini AS, Lewin NE, Mitchell GA, Abramovitz A, Kedei N, Blumberg PM, Das J. Czikora A, et al. Biochim Biophys Acta Biomembr. 2018 May;1860(5):1046-1056. doi: 10.1016/j.bbamem.2018.01.007. Epub 2018 Jan 6. Biochim Biophys Acta Biomembr. 2018. PMID: 29317197 Free PMC article. - Preventative effects of a HIF inhibitor, 17-DMAG, on partial bladder outlet obstruction-induced bladder dysfunction.
Iguchi N, Dönmez Mİ, Malykhina AP, Carrasco A Jr, Wilcox DT. Iguchi N, et al. Am J Physiol Renal Physiol. 2017 Nov 1;313(5):F1149-F1160. doi: 10.1152/ajprenal.00240.2017. Epub 2017 Aug 2. Am J Physiol Renal Physiol. 2017. PMID: 28768664 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous